RT Journal Article
SR Electronic
T1 Strategies and action points to ensure equitable uptake of COVID-19 vaccinations: A national qualitative interview study to explore the views of undocumented migrants, asylum seekers, and refugees
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.12.21255313
DO 10.1101/2021.04.12.21255313
A1 Deal, Anna
A1 Hayward, Sally E
A1 Huda, Mashal
A1 Knights, Felicity
A1 Crawshaw, Alison F
A1 Carter, Jessica
A1 Hassan, Osama B
A1 Farah, Yasmin
A1 Ciftci, Yusuf
A1 Rowland-Pomp, May
A1 Rustage, Kieran
A1 Goldsmith, Lucy
A1 Hartmann, Monika
A1 Mounier-Jack, Sandra
A1 Burns, Rachel
A1 Miller, Anna
A1 Wurie, Fatima
A1 Campos-Matos, Ines
A1 Majeed, Azeem
A1 Hargreaves, Sally
A1 ,
YR 2021
UL http://medrxiv.org/content/early/2021/04/19/2021.04.12.21255313.abstract
AB Introduction Early evidence confirms lower COVID-19 vaccine uptake in established ethnic minority populations, yet there has been little focus on understanding vaccine hesitancy and barriers to vaccination in migrants. Growing populations of precarious migrants (including undocumented migrants, asylum seekers and refugees) in the UK and Europe are considered to be under-immunised groups and may be excluded from health systems, yet little is known about their views on COVID-19 vaccines specifically, which are essential to identify key solutions and action points to strengthen vaccine roll-out.Methods We did an in-depth semi-structured qualitative interview study of recently arrived migrants (foreign-born, >18 years old; <10 years in the UK) to the UK with precarious immigration status between September 2020 and March 2021, seeking their input into strategies to strengthen COVID-19 vaccine delivery and uptake. We used the ‘Three Cs’ model (confidence, complacency and convenience) to explore COVID-19 vaccine hesitancy, barriers and access. Data were analysed using a thematic framework approach. Data collection continued until data saturation was reached, and no novel concepts were arising. The study was approved by the University of London ethics committee (REC 2020.00630).Results We approached 20 migrant support groups nationwide, recruiting 32 migrants (mean age 37.1 years; 21 [66%] female; mean time in the UK 5.6 years [SD 3.7 years]), including refugees (n = 3), asylum seekers (n = 19), undocumented migrants (n = 8) and migrants with limited leave to remain (n = 2) from 15 different countries (5 WHO regions). 23 (72%) of 32 migrants reported being hesitant about accepting a COVID-19 vaccine and communicated concerns over vaccine content, side-effects, lack of accessible information in an appropriate language, lack of trust in the health system and low perceived need. Participants reported a range of barriers to accessing the COVID-19 vaccine and expressed concerns that their communities would be excluded from or de-prioritised in the roll-out. Undocumented migrants described fears over being charged and facing immigration checks if they present for a vaccine. All participants (n = 10) interviewed after recent government announcements that COVID-19 vaccines can be accessed without facing immigration checks remained unaware of this. Participants stated that convenience of access would be a key factor in their decision around whether to accept a vaccine and proposed alternative access points to primary care services (for example, walk-in centres in trusted places such as foodbanks, community centres and charities), alongside promoting registration with primary care for all, and working closely with communities to produce accessible information on COVID-19 vaccination.Conclusions Precarious migrants may be hesitant about accepting a COVID-19 vaccine and face multiple and unique barriers to access, requiring simple but innovative solutions to ensure equitable access and uptake. Vaccine hesitancy and low awareness around entitlement and relevant access points could be easily addressed with clear, accessible, and tailored information campaigns, co-produced and delivered by trusted sources within marginalised migrant communities. These findings have immediate relevance to the COVID-19 vaccination initiatives in the UK and in other European and high-income countries with diverse migrant populations.Funding NIHRCompeting Interest StatementThe authors have declared no competing interest.Funding StatementThis work has been funded by the NIHR (NIHR300072). AD and SEH are funded by the MRC (MR/N013638/1). SH and AFC are funded by the NIHR (NIHR Advanced Fellowship NIHR300072) and the Academy of Medical Sciences (SBF005\1111). This work has been supported by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Infections in Travellers and Migrants (ESGITM). JC is funded by a National Institute for Health Research (NIHR) in-practice clinical fellowship (NIHR300290). FK is supported by a Health Education England / National Institute for Health Research (NIHR) Academic Clinical Fellowship. Kieran Rustage is funded by the Rosetrees Trust (M775). SMJ was funded by the National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Immunisation at the London School of Hygiene and Tropical Medicine (LSHTM) in partnership with Public Health England (PHE). AM is supported by the NIHR Applied Research Collaboration (ARC) NW London. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the University of London ethics committee (REC 2020.00630).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data will be made available on the St George's repository.